Overview

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Bevacizumab
Camptothecin
Cetuximab
Everolimus
Irinotecan
Sirolimus